Daiichi Sankyo, Inc. and Eli Lilly and
Company LLY today announced new results of two retrospective,
observational, comparative effectiveness studies of U.S. hospital data
comparing rates of readmission for subsequent heart attack and initial
hospitalization costs among patients with acute coronary syndromes (ACS)
treated with a percutaneous coronary intervention (PCI) and antiplatelet
therapy, including Effient^® (prasugrel) or Plavix^®(clopidogrel). The
findings were presented at the 24^th annual Transcatheter Cardiovascular
Therapeutics (TCT) scientific symposium. Sponsored by the Cardiovascular
Research Foundation (CRF), TCT is the world's premier educational meeting
specializing in interventional cardiovascular medicine.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in